All In Biotech

Drug Trial Radar · NCT04718103

A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype

Last checked: Nov 20, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 397 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

397

Actual

Start

Feb 4, 2021

Primary completion

Apr 11, 2024

Study completion Apr 11, 2024

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
IQVIA Pty Ltd
First posted
Jan 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the efficacy and safety of GSK3511294 (Depemokimab) as an adjunctive therapy in participants with severe uncontrolled asthma with an eosinophilic phenotype.

Conditions

  • Asthma

Interventions

  • GSK3511294Biological

    GSK3511294 was administered using a pre-filled syringe.

  • PlaceboBiological

    Placebo was administered as normal saline using a pre-filled syringe.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Rate of Clinically Significant Exacerbations up to 52 WeeksTime frame: Up to Week 52

Locations

129 sites in 11 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Alabaster, Alabama

  • GSK Investigational Site

    Mobile, Alabama

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Beverly Hills, California

  • GSK Investigational Site

    Lancaster, California

  • GSK Investigational Site

    Colorado Springs, Colorado

  • GSK Investigational Site

    Lafayette, Colorado

  • GSK Investigational Site

    Aventura, Florida

  • GSK Investigational Site

    Hialeah, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami Lakes, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Evanston, Illinois

  • GSK Investigational Site

    Columbia, Maryland

  • GSK Investigational Site

    Dearborn, Michigan

  • GSK Investigational Site

    Ypsilanti, Michigan

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Northfield, New Jersey

  • GSK Investigational Site

    Toms River, New Jersey

  • GSK Investigational Site

    The Bronx, New York

  • GSK Investigational Site

    Huntersville, North Carolina

  • GSK Investigational Site

    Winston-Salem, North Carolina

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Edmond, Oklahoma

  • GSK Investigational Site

    Altoona, Pennsylvania

  • GSK Investigational Site

    DuBois, Pennsylvania

  • GSK Investigational Site

    Hershey, Pennsylvania

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Rapid City, South Dakota

  • GSK Investigational Site

    Allen, Texas

  • GSK Investigational Site

    Boerne, Texas

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    San Antonio, Texas

  • GSK Investigational Site

    San Antonio, Texas

  • GSK Investigational Site

    San Antonio, Texas

  • GSK Investigational Site

    Bellingham, Washington

Showing 40 of 129 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.